For women who require treatment with quetiapine during pregnancy, the available reproductive safety data are generally reassuring. The largest body of evidence does not suggest a meaningful increase in major congenital malformations, while metabolic effects, particularly gestational diabetes, remain an important consideration.
New registry data found no major malformations among 58 infants exposed to cariprazine in the first trimester, offering reassuring but preliminary reproductive safety evidence.
Exposure to long-acting injectable and oral second-generation antipsychotics during pregnancy was associated with similar obstetric outcomes in a large retrospective study.
This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.
New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
The most recent publication from the National Pregnancy Registry focuses on overall risk of malformations associated with the class of antipsychotic medications.
